Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 29

1.

The lytic activity of VSV-GP treatment dominates the therapeutic effects in a syngeneic model of lung cancer.

Schreiber LM, Urbiola C, Das K, Spiesschaert B, Kimpel J, Heinemann F, Stierstorfer B, Müller P, Petersson M, Erlmann P, von Laer D, Wollmann G.

Br J Cancer. 2019 Sep 18. doi: 10.1038/s41416-019-0574-7. [Epub ahead of print]

PMID:
31530903
2.

RSV Vaccine Based on Rhabdoviral Vector Protects after Single Immunization.

Wilmschen S, Schneider S, Peters F, Bayer L, Issmail L, Bánki Z, Grunwald T, von Laer D, Kimpel J.

Vaccines (Basel). 2019 Jul 3;7(3). pii: E59. doi: 10.3390/vaccines7030059.

3.

Xenoantigen-Dependent Complement-Mediated Neutralization of Lymphocytic Choriomeningitis Virus Glycoprotein-Pseudotyped Vesicular Stomatitis Virus in Human Serum.

Pipperger L, Koske I, Wild N, Müllauer B, Krenn D, Stoiber H, Wollmann G, Kimpel J, von Laer D, Bánki Z.

J Virol. 2019 Aug 28;93(18). pii: e00567-19. doi: 10.1128/JVI.00567-19. Print 2019 Sep 15.

4.

Oncolytic virotherapy enhances the efficacy of a cancer vaccine by modulating the tumor microenvironment.

Koske I, Rössler A, Pipperger L, Petersson M, Barnstorf I, Kimpel J, Tripp CH, Stoitzner P, Bánki Z, von Laer D.

Int J Cancer. 2019 Oct 1;145(7):1958-1969. doi: 10.1002/ijc.32325. Epub 2019 Apr 29.

PMID:
30972741
5.

Induction of Tier 1 HIV Neutralizing Antibodies by Envelope Trimers Incorporated into a Replication Competent Vesicular Stomatitis Virus Vector.

Bresk CA, Hofer T, Wilmschen S, Krismer M, Beierfuß A, Effantin G, Weissenhorn W, Hogan MJ, Jordan APO, Gelman RS, Montefiori DC, Liao HX, Schmitz JE, Haynes BF, von Laer D, Kimpel J.

Viruses. 2019 Feb 15;11(2). pii: E159. doi: 10.3390/v11020159.

6.
7.

Oncolytic activity of the rhabdovirus VSV-GP against prostate cancer.

Urbiola C, Santer FR, Petersson M, van der Pluijm G, Horninger W, Erlmann P, Wollmann G, Kimpel J, Culig Z, von Laer D.

Int J Cancer. 2018 Apr 26. doi: 10.1002/ijc.31556. [Epub ahead of print]

8.

The Oncolytic Virus VSV-GP Is Effective against Malignant Melanoma.

Kimpel J, Urbiola C, Koske I, Tober R, Banki Z, Wollmann G, von Laer D.

Viruses. 2018 Mar 2;10(3). pii: E108. doi: 10.3390/v10030108.

9.

Application of interferon modulators to overcome partial resistance of human ovarian cancers to VSV-GP oncolytic viral therapy.

Dold C, Rodriguez Urbiola C, Wollmann G, Egerer L, Muik A, Bellmann L, Fiegl H, Marth C, Kimpel J, von Laer D.

Mol Ther Oncolytics. 2016 Sep 28;3:16021. eCollection 2016.

10.

Superior Therapeutic Index in Lymphoma Therapy: CD30(+) CD34(+) Hematopoietic Stem Cells Resist a Chimeric Antigen Receptor T-cell Attack.

Hombach AA, Görgens A, Chmielewski M, Murke F, Kimpel J, Giebel B, Abken H.

Mol Ther. 2016 Aug;24(8):1423-34. doi: 10.1038/mt.2016.82. Epub 2016 Apr 26.

11.

Exclusive Transduction of Human CD4+ T Cells upon Systemic Delivery of CD4-Targeted Lentiviral Vectors.

Zhou Q, Uhlig KM, Muth A, Kimpel J, Lévy C, Münch RC, Seifried J, Pfeiffer A, Trkola A, Coulibaly C, von Laer D, Wels WS, Hartwig UF, Verhoeyen E, Buchholz CJ.

J Immunol. 2015 Sep 1;195(5):2493-501. doi: 10.4049/jimmunol.1500956. Epub 2015 Jul 31.

12.

Differences in male and female nurses' responses to physical assault by psychiatric patients: a supplemental finding of a mixed-methods study.

Moylan LB, Cullinan MB, Kimpel JE.

J Psychosoc Nurs Ment Health Serv. 2014 Dec 1;52(12):36-42. doi: 10.3928/02793695-20140903-01. Epub 2014 Sep 30.

PMID:
25250791
13.

Re-engineering vesicular stomatitis virus to abrogate neurotoxicity, circumvent humoral immunity, and enhance oncolytic potency.

Muik A, Stubbert LJ, Jahedi RZ, Geiβ Y, Kimpel J, Dold C, Tober R, Volk A, Klein S, Dietrich U, Yadollahi B, Falls T, Miletic H, Stojdl D, Bell JC, von Laer D.

Cancer Res. 2014 Jul 1;74(13):3567-78. doi: 10.1158/0008-5472.CAN-13-3306. Epub 2014 May 8.

14.

VSV-GP: a potent viral vaccine vector that boosts the immune response upon repeated applications.

Tober R, Banki Z, Egerer L, Muik A, Behmüller S, Kreppel F, Greczmiel U, Oxenius A, von Laer D, Kimpel J.

J Virol. 2014 May;88(9):4897-907. doi: 10.1128/JVI.03276-13. Epub 2014 Feb 19.

15.

Comparison of three humanized mouse models for adoptive T cell transfer.

Volk A, Hartmann S, Muik A, Geiss Y, Königs C, Dietrich U, von Laer D, Kimpel J.

J Gene Med. 2012 Aug;14(8):540-8. doi: 10.1002/jgm.2652.

PMID:
22847974
16.

Lens epithelium-derived growth factor/p75 qualifies as a target for HIV gene therapy in the NSG mouse model.

Vets S, Kimpel J, Volk A, De Rijck J, Schrijvers R, Verbinnen B, Maes W, Von Laer D, Debyser Z, Gijsbers R.

Mol Ther. 2012 May;20(5):908-17. doi: 10.1038/mt.2012.6. Epub 2012 Feb 14.

17.

Retroviral insertional mutagenesis can contribute to immortalization of mature T lymphocytes.

Newrzela S, Cornils K, Heinrich T, Schläger J, Yi JH, Lysenko O, Kimpel J, Fehse B, von Laer D.

Mol Med. 2011;17(11-12):1223-32. doi: 10.2119/molmed.2010.00193. Epub 2011 Jul 27.

18.

Secreted antiviral entry inhibitory (SAVE) peptides for gene therapy of HIV infection.

Egerer L, Volk A, Kahle J, Kimpel J, Brauer F, Hermann FG, von Laer D.

Mol Ther. 2011 Jul;19(7):1236-44. doi: 10.1038/mt.2011.30. Epub 2011 Mar 1.

19.

Survival of the fittest: positive selection of CD4+ T cells expressing a membrane-bound fusion inhibitor following HIV-1 infection.

Kimpel J, Braun SE, Qiu G, Wong FE, Conolle M, Schmitz JE, Brendel C, Humeau LM, Dropulic B, Rossi JJ, Berger A, von Laer D, Johnson RP.

PLoS One. 2010 Aug 23;5(8):e12357. doi: 10.1371/journal.pone.0012357.

20.

FREEDOM TO OPERATE: Intellectual Property Protection in Plant Biology and Its Implications for the Conduct of Research.

Kimpel JA.

Annu Rev Phytopathol. 1999 Sep;37:29-51. doi: 10.1146/annurev.phyto.37.1.29.

PMID:
11701816
21.
22.

Plant responses to environmental stress.

Vierling E, Kimpel JA.

Curr Opin Biotechnol. 1992 Apr;3(2):164-70. Review.

PMID:
1368289
23.

Regulation of the heat shock response in soybean seedlings.

Kimpel JA, Nagao RT, Goekjian V, Key JL.

Plant Physiol. 1990 Nov;94(3):988-95.

24.

Molecular and cellular biology of the heat-shock response.

Nagao RT, Kimpel JA, Key JL.

Adv Genet. 1990;28:235-74. Review. No abstract available.

PMID:
2239450
25.

Presence of Heat Shock mRNAs in Field Crown Soybeans.

Kimpel JA, Key JL.

Plant Physiol. 1985 Nov;79(3):672-8.

26.
27.

[Oligodendroglioma. Clinical course in relation to histological grading].

Neumann J, Kimpel J, Gulotta F.

Neurochirurgia (Stuttg). 1978 Mar;21(2):35-42. German.

PMID:
643146
28.
29.

De l'intérêt de la compression aucours de la cholecystographie.

CHENE P, KIMPEL J.

Gaz Med Fr. 1946 Sep;53(17):470. Undetermined Language. No abstract available.

PMID:
20280931

Supplemental Content

Loading ...
Support Center